To the editor: In urban area of industrial countries, the ocular surface is exposed daily to intense burden of particulate matter, ozone, carbon monoxide, nitrogen dioxide (NO~2~) and sulfur dioxide produced by fossil fuel. Air pollution is a causative factor for various ocular surface complaints such as eye redness, irritation and blurring of vision, as well as various ocular diseases such as meibomian gland disease and dry eye disease, vernal keratoconjunctivitis, allergic conjunctivitis, retinal vein and artery occlusion, and glaucoma.[@R1] Putative pathophysiology of air pollutants is mediated by oxidative stress in ocular tissues exposed to atmospheric changes involving damage of cellular DNA, membrane lipids peroxidation, inactivation of receptor protein and enzymes, and finally cells apoptosis and autophagy mediated by autophagosome.[@R3] Similarly, air pollutants promote neurotoxic and microvascular effects impacting on cardiovascular diseases as well as glaucoma and retinal vascular diseases.[@R2] Since 8 December 2019, the world has been confronted by a viral pneumonia pandemic caused by the coronavirus named Severe Acute Respiratory Syndrome (SARS-CoV-2) or Coronavirus Disease 2019 (COVID-19). Initially described in Wuhan, Hubei, in the Peoples Republic of China, the movement of people and freight through tourism and commercial airline flights contributed to the spread of the global pandemic, causing millions of cases and tens of thousands of deaths. The local authorities responded quickly to promulgate quarantine status of epicentres such as towns, popular districts, production plants and other gathering places. Consequently, the reduction of human activities has impacted on greenhouse gas emissions from industry, tertiary services, mass transits or individual car circulation. NASA's Aura satellite described a marked reduction of nitrous oxide (NO~2~) across China from 1--20 January 2020 (before the quarantine) to 10--25 February (during the quarantine).[@R8] According to NASA scientists, the reduction in NO~2~ pollution was first apparent near Wuhan, but eventually spread across the country and around the world. A similar NO~2~ decrease across Europe, China and India were identified by Copernicus Sentinel-5P satellite, from the European Union Copernicus programme, during quarantine.[@R10] Globally, an NO~2~ decrease of 40%--50% over major cities across Asia, Europe or North America were measured following the decrease of global economy due to coronavirus epidemic ([figure 1](#F1){ref-type="fig"}).[@R8] The impact of the global reduction of air pollution during SARS-CoV-2 pandemic could positively affect all the biodiversity of Earth, involving the slowdown of climatic change and the quality of freshwater. Therefore, the strong efforts of the international community to contain the COVID-19 epidemic may also have indirect health benefits by lowering the impact of air pollution on ocular diseases. Even if SARS-CoV-2 involves conjunctivitis and external ocular infections,[@R12] there are not yet published data describing the effects of a reduction of air pollutants on the ocular surface during the quarantine period, and a putative decrease in some ocular complaints---individuals being at home and less exposed to pollens and atmospheric pollutants. However, all activities soliciting the near vision and accommodation were particularly increased during quarantine such as videogames, television, tele-working, reading and others activities in smartphone, putatively generating dry eye symptoms and visual fatigue.[@R13] Also, it should be noted that a large number of doctors accidentally acquired coronavirus infection by contact with oropharyngeal fluids, but also tears and conjunctival secretions of patients[@R14]---particularly for patients with conjunctivitis.[@R15] Furthermore, recent data highlighted that ocular symptoms could occur about 10--15 days after systemic contamination, with a low positivity rate of reverse transcription-PCR in tears and conjunctival samples (ie, conjunctival swab or/and scrapping).[@R16] SARS-CoV-2 patients without any ocular symptoms could also excreted SARS-CoV-2 in tears.[@R18] Even if SARS-CoV-2 is an enveloped virus surviving a few hours or days on dry inert surfaces, the contaminated surfaces of ophthalmological consultation rooms are an established route of SARS-CoV-2 spreading.[@R19] Thus, ophthalmologists are mainly concerned by an aerosol transmission, working in confined spaces at few centimetres from the faces of their patients, and a transmission by contact with tears or contaminated surfaces. Considering the contagiousness of the SARS-CoV-2, personal protective equipment is necessary in daily clinical practice: gloves and filtering face piece respirators (FFP2 or FFP3 masks) for the ophthalmologist and surgical facemasks for the patient.[@R20] A plexiglass barrier (protective shield) between patient and ophthalmologist is as additional salient approach during close clinical and paraclinical examinations.[@R21] Those preventive measures against SARS-CoV-2 will increase the duration of consultation, which will increase the waiting list for patients---that is already long and that may further delay medical treatment.[@R22] In conclusion, even if individuals are less exposed to air pollutants and environmental allergens during quarantine weeks, SARS-CoV-2 seems to be a foe both for ophthalmologists---with a risk of infection through contact with eye secretions of patients---and for patients---with a delay in their medical management. The SARS-CoV-2 will probably upset ophthalmological practices during the forthcoming months or years.
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